Summary:
- The article explores the application of transient CAR-T cell therapy—traditionally used in oncology—as a potential mechanism for inducing immune tolerance in severe allergic conditions.
- It proposes utilizing mRNA-based delivery systems to achieve "transient" expression of chimeric antigen receptors, thereby minimizing long-term risks such as off-target toxicity or permanent B-cell depletion.
- The author discusses the engineering challenges of redirecting CAR-T cells to target allergen-specific memory B-cells and plasma cells while maintaining a favorable safety profile for non-oncological patients.